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OBJECTIVES: To compare the total costs of XELOX (oral capecitabine  IV oxali-
platin) o bevacizumab versus FOLFOX-4 (IV 5-FU/ folinic acid/ oxaliplatin) o beva-
cizumab in the ﬁrst line treatment for patients with metastatic colorectal cancer 
(mCRC) in Saudi Arabia from a health care provider and societal perspectives. 
METHODS: The analysis was based on a non-inferiority phase III clinical trial data 
done by Cassidy et al. in 2008. Direct medical and indirect costs were contrasted. 
Drug acquisition costs were estimated using published sources. Drug administration 
costs for each regimen and hospitalisation costs were calculated using values derived 
from a Saudi Arabian-speciﬁc survey and observation. Data taken directly from the 
trial and used in the analysis include treatment duration, adverse event frequency and 
central venous access management. Indirect costs derived from the time that the patient 
incurred in the chemotherapy administration process and the time consumed by travel-
ling to the health care centre. RESULTS: Total direct medical cost estimates were 
considerably lower for 3-weekly XELOX compared with bi-weekly FOLFOX that 
resulted in savings equivalent to SR 42,660 (US$ 11,346) per patient which were 
mainly due to lower drug administration costs. Correspondingly, total direct medical 
cost estimates were substantially lower for XELOX  bevacizumab compared with 
FOLFOX  bevacizumab by SR 55,236 (US$ 14,690) per patient. The drug acquisition 
costs was higher for XELOX. However, this was offset by XELOX’s reductions in 
other health care resources consumption such as the use of central venous access and 
other medications. Regarding indirect cost estimates, patient time and travel costs were 
lower for XELOX by SR 5815 (US$ 1547) per patient due to fewer visits and cycles. 
CONCLUSIONS: XELOX o bevacizumab is cost-saving in comparison to FOLFOX-4 
o bevacizumab from both health care provider and societal perspective in Saudi 
Arabia.
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OBJECTIVES: Surgical treatment of colon cancer requires resection of the tumor mass 
and formation of anastomosis, such as a latero-lateral. Two common methods to 
construct an anastomosis are the use of staplers (SA) and hand suturing (HA) 
(MacRae, 1998; Lustosa, 2002). Our objective was to compare costs and resources 
for both surgery techniques to assess the potential cost-savings due to surgery time 
reduction, faster recovery and less complications by the adoption of staplers, under 
the public payer perspective, in Brazil. METHODS: A decision tree was developed to 
compare costs and resources for SA versus HA surgical techniques, based on Brazilian 
guidelines for HTA (Vianna, 2007). Similar efﬁcacy was assumed based on CHOY, 
2009, and a panel of specialists was conducted to obtain the local practice. Only direct 
medical costs (anesthesia drugs, physician fees, hospital length-of-stay (LOS) and 
materials) were considered based on public lists (SIMPRO, 2009; CBHPM 5th edition). 
One-month timeframe was considered, based on intra and post-operative periods; 
consequently a discount rate was not necessary. One-way sensitivity analyses were 
performed to assess the robustness of the results. RESULTS: Total costs were 1.5% 
higher for SA than HA (R$7498 versus R$7389), because of stapler’s costs (R$ 1,992 
versus R$ 39 for suture). However, SA technique allowed the reduction on operating 
room costs due to reduction of 2 hours on surgery (4 versus 6 hours), anesthesia drugs 
and oxygen (R$ 4,009 versus R$4574; 12% of reduction). The SA procedure, also, 
reduced the LOS (6 versus 8 days; R$1481 versus R$2715) and the complication costs 
with ﬁstulas and intracavitary abscess (R$15.19 versus R$60.49). CONCLUSIONS: 
Findings suggest SA technique as a safety and effective choice for colon cancer surger-
ies, compared with HA, that can reduce use of resources that could offset stapler’s 
costs, under Brazilian public payer perspective.
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OBJECTIVES: Surgical treatment of colon cancer requires resection of the tumor mass 
and formation of anastomosis, such as a latero-lateral. Two common methods to 
construct an anastomosis are the use of staplers (SA) and hand suturing (HA) 
(MacRae, 1998; Lustosa, 2002). Our objective was to compare costs and resources 
for both surgery techniques to assess the potential cost-savings due to surgery time 
reduction, faster recovery and less complications by the adoption of staplers, under 
private payer perspective, in Brazil. METHODS: A decision tree was developed to 
compare costs and resources for SA versus HA surgical techniques, based on Brazilian 
guidelines for HTA (Vianna, 2007). Similar efﬁcacy was assumed based on CHOY, 
2009, and a panel of specialists was conducted to obtain the local practice. Only direct 
medical costs (anesthesia drugs, physician fees, hospital length-of-stay (LOS) and 
materials) were considered based on public lists (SIMPRO, 2009; CBHPM 5th edition). 
One-month timeframe was considered, based on intra and post-operative periods; 
consequently a discount rate was not necessary. One-way sensitivity analyses were 
performed to assess the robustness of the results. RESULTS: Total costs were 8.5% 
higher for SA than HA (R$8449 versus R$7785), because of stapler’s costs (R$4246 
versus R$85 for suture). However, SA technique allowed the reduction on operating 
room costs due to reduction of 2 hours on surgery (4 versus 6 hours; 33% less time), 
anesthesia drugs and oxygen (R$2316 versus R$2875; 19% of reduction). The SA 
procedure, also, reduced the LOS (6 versus 8 days; R$1872 versus R$4768) and the 
complication costs with ﬁstulas and intracavitary abscess (R$14.29 versus R$56.63). 
CONCLUSIONS: Findings suggest SA technique as a safety and effective choice for 
colon cancer surgeries, compared with HA, that can reduce use of resources that could 
offset stapler’s costs, under Brazilian private payer.
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OBJECTIVES: Colorectal cancer (CRC) is the second most commonly diagnosed 
cancer and the third cause of cancer-related mortality in Taiwan. Capecitabine 
(Xeloda®), an oral ﬂuoropyrimidine, is an effective alternative to intravenous ﬂuoro-
uracil plus leucovorin (5-FU/LV) in treatment of metastasis colon cancer (mCRC). 
Recently, the addition of oxaliplatin to 5-FU/LV (FOLFOX) or capecitabine (XELOX) 
have been proven in signiﬁcantly improving the progression free survival and overall 
survival compared with single agent. Based on the result of study NO16966 (Cassidy 
2007), there is no difference in efﬁcacy between XELOX and FOLFOX. The objective 
of this study was to develop a pharmacoeconomic model to estimate the medical 
resource utilization (MRU) of XELOX vs. FOLFOX as ﬁrst line treatment of mCRC 
from the payer’s [Bureau of National Health Insurance (BNHI)] perspective. 
METHODS: A cost-minimization model was constructed to represent the real MRU 
of XELOX and FOLFOX. Local treatment regimens and drugs administration pat-
terns were based on the results of expert panel survey conducted among 13 colorectal 
surgeons and medical oncologists. Clinical outcomes and adverse events (AEs) inci-
dence were referred to the result of study NO16996. Unit costs were estimated from 
BNHI fee schedules and local expert opinion. Sensitivity analyses were performed on 
key model parameters. RESULTS: The result showed drug cost was estimated to 
be higher in the XELOX (NTD$259,618 vs. NTD$204,442) by 6 months. However, 
these cost increments were offset by the drug administration cost and AEs management 
cost of FOLFOX. The drug administration cost and AEs management cost in the 
FOLFOX and XELOX were NTD$119,285 vs. NTD$24,090 and NTD$14,414 vs. 
NTD$7,155, respectively. FOLFOX regimen required more physician visits, drug 
infusion times and hospitalizations. As a result, XELOX demonstrated a signiﬁcant 
overall cost savings of NTD$47,277. CONCLUSIONS: From the perspective of 
Taiwan BNHI, this study showed that XELOX is cost-saving in comparison with 
FOLFOX in the ﬁrst line treatment of mCRC.
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OBJECTIVES: To assess the cost-effectiveness of pemetrexed/cisplatin vs. gemcitabine/
cisplatin in the ﬁrst-line treatment of advanced or metastatic non-small cell lung 
cancer (NSCLC) patients with an adenocarcinoma tumour histology. METHODS: A 
Markov model developed to estimate the costs and beneﬁts of pemetrexed/cisplatin 
vs. gemcitabine/cisplatin in the ﬁrst-line treatment of NSCLC patients was populated 
with Italian unit cost data. As the incidence and prevalence of adenocarcinoma is 
higher than any other type of non-squamous NSCLC in Italy, the model focuses on 
patients with adenocarcinoma histology. The model consists of health states for stable 
disease, response, progressive disease and death. Patients receiving chemotherapy 
could also experience adverse events within the stable and response states. The clinical 
inputs (response rates, overall survival, progression-free survival and adverse event 
rates) were obtained from a phase III randomised trial comparing pemetrexed/cisplatin 
and gemcitabine/cisplatin. The analysis was from the Italian health care system per-
spective, with a 3–year horizon. Outcomes included direct medical costs (chemother-
apy; adverse events; best supportive care; terminal/palliative care), life years gained 
(LYG) and quality-adjusted life years (QALYs), all discounted at a rate of 3%. 
RESULTS: Total LYG was 1.26 for patients treated with pemetrexed/cisplatin and 
1.15 for patients treated with gemcitabine/cisplatin. Total QALYs were 0.67 for the 
